Considerations regarding a permitted daily exposure calculation for ethyl methanesulfonate

Toxicology Letters

Volumn 190, Issue 3, 2009, Pages 330-332

  Müller, Lutz ^a   Gocke, Elmar ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Ethyl methanesulfonate; Exposure limitation; Mutation threshold; Permitted daily exposure; Risk assessment

Indexed keywords

MESYLIC ACID ETHYL ESTER;

ARTICLE; CANCER RISK; DRUG IMPURITY; EXPOSURE; GENE MUTATION; GENOTOXICITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; TOXICITY TESTING;

ALKYLATING AGENTS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CONTAMINATION; ENVIRONMENTAL EXPOSURE; ETHYL METHANESULFONATE; HUMANS; MUTAGENICITY TESTS; MUTAGENS; NEOPLASMS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RISK ASSESSMENT;

EID: 70350142575     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2009.03.015     Document Type: Article

References (14)

1. Barlow S., Renwick A.D., Kleiner J., Bridges J.W., Busk L., Dybing E., Edler L., Eisenbrand G., Fink-Gremmels J., Knaap A., Kroes R., Liem D., Müller D.J.G., Page S., Rolland V., Schlatter J., Tritscher A., Tueting W., and Würtzen G. Risk assessment of substances that are both genotoxic and carcinogenic. Report of an international conference organized by EFSA and WHO with support of ILSI Europe. Food Chem. Toxicol. 44 (2006) 1636-1650
2. CHMP, 2006. Guideline on the limits of genotoxic impurities. www.emea.europa.eu/pdfs/human/swp/519902en.pdf (June 28, 2006) with Q&A www.emea.europa.eu/pdfs/human/swp/43199407en.pdf (June 25, 2008).
3. CHMP, 2008. Questions and answers on the follow-up to the contamination of Viracept (nelfinavir) with ethyl mesilate, London, July 24, 2008. Doc. Ref. EMEA/CHMP/375807/2008, http://www.emea.europa.eu.
4. Doak S.H., Jenkins G.J., Johnson G.E., Quick E., Parry E.M., and Parry J.M. Mechanistic influences for mutation induction curves after exposure to DNA-reactive carcinogens. Cancer Res. 15 (2007) 3904-3911
5. EFSA-European Food Safety Authority, 2005. Opinion of the Scientific Committee on a request from EFSA related to a harmonised approach for risk assessment of substances which are both genotoxic and carcinogenic (request no. EFSA-Q-2004-020). Adopted on October 18, 2005. Available from: http://efsa.eu.int/science/sc_committee/sc_opinions1201/sc_op_ej282_gentox_en3.pdf.
6. Gocke E., Ballantyne M., Whitwell J., and Müller L. In vivo MNT and MutaTMmouse studies to define the dose response relations of the genotoxicity of EMS and ENU. Toxicol. Lett. 190 (2009) 286-297
7. Gocke E., and Wall M. In vivo genotoxicity of EMS: statistical assessment of the dose response curves. Toxicol. Lett. 190 (2009) 298-302
8. Gold L.S., Slone T.H., Manley N.B., Garfinkel G.B., Hudes E.S., Rohrbach L., and Ames B.N. The carcinogenic potency database: analyses of 4000 chronic animal cancer experiments published in the general literature and by the U.S. National Cancer Institute/National Toxicology Program. Environ. Health Perspect. 96 (1991) 11-15. http://potency.berkeley.edu/ (with continuous updates until 2007 at http://potency.berkeley.edu/)
9. ICH Q3C(R3), 2005. Impurities: guideline for residual solvents, http://www.ich.org/cache/compo/363-272-1.html#Q3C.
10. Kroes R., Renwick A.G., Cheeseman M., Kleiner J., Mangelsdorf I., Piersma A., Schilter B., Schlatter J., van Schothorst F., Vos J.G., and Würtzen G. Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet. Food Chem. Toxicol. 42 (2004) 65-83
11. Lavé T., Paehler A., and Grimm H.P. Modelling of patient EMS exposure: translating pharmacokinetics of EMS in vitro and in animals into patients. Toxicol. Lett. 190 (2009) 310-316
12. Müller L., Gocke E., Lavé T., and Pfister T. Ethylmethane sulfonate toxicity in Viracept-a comprehensive human risk assessment based on threshold data for mutagenicity. Toxicol. Lett. 190 (2009) 317-329
13. Swenberg J.A., Fryar-Tita E., Jeong Y.C., Boysen G., Starr T., Walker V.E., and Albertini R.J. Biomarkers in toxicology and risk assessment: informing critical dose-response relationships. Chem. Res. Toxicol. 21 (2008) 253-265
14. Walker V.E., Casciano D.A., and Tweats D.J. The Viracept-EMS case: impact and outlook. Toxicol. Lett. 190 (2009) 333-339